BioNotebook: Ten deals and a breakup; Gilead/Ono, Vernalis/Novartis, Sorrento/NantWorks and more
This article was originally published in Scrip
Gilead licenses Ono BTK Inhibitor; Novartis stops developing Vernalis drug; Sorrento partners with NantWorks, Conkwest; Xencor, Novo enter discovery collaboration; ContraVir licenses Chimerix antiviral; MiNa accesses Marina technology; Bayer takes second X-Chem program; Durect grants rights to Santen; Adapt licenses Lightlake's intranasal treatment; and Oncothyreon expands deal with Array.
You may also be interested in...
Monrovia, California-based Xencor Inc.'s latest collaboration, which is worth $150m up front and up to $2.41bn in milestone fees from Novartis AG, shows how the company is growing up as its research and development pipeline matures.
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.